Hair Care
Dizziness on GLP-1 Medication: Causes and When to Worry
Dizziness on appetite medication usually has an identifiable cause. Here is how to tell dehydration from low blood sugar...
This is one of the few areas in GLP-1 research where the published evidence genuinely points in different directions depending on which study you read. That is worth explaining honestly rather than picking whichever finding is more reassuring.
Why bone matters during rapid weight loss
Before looking at drug-specific findings, the general principle matters. Rapid weight loss, from any cause, is a recognised independent risk factor for reduced bone density. This applies to bariatric surgery, severe dieting and, plausibly, any pharmacologically accelerated weight loss.
Mechanical loading is part of why. Bone density partly responds to the load placed on it, and a lighter body places less load on the skeleton, particularly weight-bearing bones. Rapid loss may also affect hormone levels and nutrient status in ways that influence bone turnover.
This general principle applies regardless of what specifically is causing the weight loss, which matters when interpreting drug-specific research below.
What the tirzepatide-specific research found
A large retrospective cohort study using the TriNetX database, Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists, found initiation of tirzepatide was associated with a significantly higher risk of osteoporosis or fragility fractures compared with other GLP-1 receptor agonists, and a higher likelihood of subsequently starting osteoporosis treatment.
Separately, animal research examining tirzepatide in obese mice found it promoted bone loss, with the researchers linking this to gut microbial metabolites, suggesting a specific mechanism rather than only the general rapid-weight-loss effect covered above.
What the semaglutide-specific research found
A phase 2 randomised, double-blinded trial, Once-weekly semaglutide versus placebo in adults with increased fracture risk, conducted over 52 weeks, found lumbar spine and total hip bone mineral density were lower in the semaglutide group compared with placebo.
This is a directly randomised comparison, which carries more weight than an observational cohort study, and it points the same direction as the tirzepatide findings: reduced bone density associated with treatment.
What the broader meta-analyses found
Here is where the picture becomes genuinely contradictory rather than simply confirming the individual studies above.
A meta-analysis across GLP-1 receptor agonists as a class found no significant effect on elevated fracture risk overall, and reported a statistically significant improvement in bone mineral density and certain bone turnover markers in some analyses.
A separate systematic review concluded GLP-1 receptor agonists had a neutral impact on bone mineral density overall.
How to make sense of the contradiction
Several things likely explain why these findings diverge.
Population differences. Studies in type 2 diabetes populations, where these drugs were originally studied, may show different bone effects than studies in people using them primarily for weight loss, given the different starting metabolic profile.
Drug-specific differences. Tirzepatide's dual GIP and GLP-1 mechanism may behave differently from GLP-1-only drugs regarding bone, consistent with the animal research suggesting a specific gut-microbiome-related pathway.
Study design differences. Randomised trials, observational cohorts and meta-analyses pooling heterogeneous studies can produce different signals even when examining a similar underlying question, particularly for an outcome like fracture risk that requires long follow-up and large sample sizes to detect reliably.
The confound of weight loss itself. Since rapid weight loss independently affects bone density regardless of cause, separating a drug-specific effect from a weight-loss-mediated effect is genuinely difficult in observational data.
What this means practically
The honest position, given genuinely mixed evidence, is that bone health deserves attention during any substantial GLP-1-related weight loss, without either dismissing the concern or treating it as definitively established harm.
This applies with more force to tirzepatide specifically, given that both the human cohort data and the animal mechanistic data point the same direction for that particular drug.
Muscle-protective measures also protect bone, since resistance training loads the skeleton mechanically. This connects directly to the protein and resistance training guidance covered throughout this series for muscle preservation, which serves a dual purpose here.
Adequate calcium and vitamin D matter, particularly given how common vitamin D deficiency is across South Asia independent of any weight loss treatment.
People with existing osteoporosis risk factors warrant particular attention: postmenopausal women, given the additional bone loss from declining oestrogen covered in our guide to menopause weight gain, anyone with a family history of osteoporosis, and anyone with other risk factors such as long-term steroid use or a previous fragility fracture.
What to actually do
Discuss bone health specifically if you are considering or using tirzepatide, particularly with additional risk factors present.
Resistance train, which serves the dual purpose of preserving both muscle and bone during any weight loss approach.
Ensure adequate calcium and vitamin D intake, and consider testing vitamin D levels given regional deficiency prevalence.
Avoid unnecessarily rapid weight loss, since the rate of loss itself, separate from any specific drug mechanism, affects bone density.
Consider bone density testing if you have additional risk factors and are pursuing substantial, sustained weight loss through any method.
Where this leaves the decision
None of this evidence describes METASLIM™ GLP-1 sublingual supplement, which is a physician-reviewed supplement rather than pharmaceutical semaglutide or tirzepatide. The research in this article concerns pharmaceutical GLP-1 receptor agonists specifically.
The general principle, that rapid weight loss from any cause affects bone density and that resistance training and adequate calcium and vitamin D protect against it, applies regardless of method, which is why our physician-guided weight loss program includes activity guidance alongside appetite support rather than appetite reduction alone.
Our guide to long-term safety of GLP-1 drugs covers the broader evidence picture, and protein for weight loss covers the muscle preservation that also protects bone.
The summary
A large real-world cohort study found tirzepatide associated with higher osteoporosis and fragility fracture risk than other GLP-1 drugs, supported by animal mechanistic research.
A randomised semaglutide trial found lower bone mineral density in the treatment group over 52 weeks.
Broader meta-analyses across the drug class found no significant fracture risk increase overall, with some showing improved bone density markers, creating a genuinely contradictory evidence picture.
Rapid weight loss from any cause independently affects bone density, which complicates separating drug-specific effects from weight-loss-mediated effects.
Resistance training, adequate calcium and vitamin D, and avoiding unnecessarily rapid loss all help regardless of which underlying evidence proves correct.
Get started with a physician review that can discuss bone health alongside your other risk factors.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.